Newsletter
Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

JAMA Editor’s Summary

Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the
June 26, 2018

Fruquintinib for Refractory Metastatic CRC, Abortion Facility Type and Procedural Complications, Screening for Osteoporosis, and more

Editor’s Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the June 26, 2018 issue

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

Proudly supported by:

cover
Reducing Mental Health Stigma among Healthcare Professionals featuring Corey Feist Reducing mental health stigma and mental health and well-being among healthcare professionals.